SCHEMBL7708241

SCHEMBL7708241

CC1Oc2ccc(CN(Cc3c(F)cccc3Cl)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
HTT P42858 2/20 0.33
POLB P06746 2/20 0.33
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
MITF O75030 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.32
TSHR P16473 2/20 0.32
KMT2A Q03164 2/20 0.32
SLC22A12 Q96S37 1/20 0.32
KCNA5 P22460 1/20 0.32
PARP1 P09874 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704809 0.91 PARP1 (0.41) ALDH1A1HTTPOLBABL1RIN1
SCHEMBL7704942 0.87 ALDH1A1 (0.37) ALDH1A1HTTPOLBLMNAMAPT
SCHEMBL7711006 0.87 PARP1 (0.36) ALDH1A1HTTPOLBLMNAMAPT
SCHEMBL6302929 0.86 PARP1 (0.35) ALDH1A1HSD17B10TSHRKMT2APARP1
SCHEMBL7712797 0.86 RIPK1 (0.36) ALDH1A1LMNAMAPTHSD17B10TSHR
SCHEMBL7708255 0.86 RIPK1 (0.36) HSD17B10TSHRPARP1SMN1; SMN2
SCHEMBL6428132 0.85 RIPK1 (0.36) HSD17B10TSHRPARP1SMN1; SMN2
SCHEMBL7704932 0.85 HDAC3 (0.35) MAPTHSD17B10PARP1
SCHEMBL6309617 0.84 HDAC1 (0.43) ALDH1A1HTTMAPK1NPSR1HSD17B10
SCHEMBL7704945 0.84 HDAC3 (0.44) ALDH1A1HTTMAPK1NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed